Cafepharma Today

May 22 2025 - Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population
Prices for new US drugs doubled in 4 years as focus on rare disease grows
FDA expands warnings of heart risks on COVID shots
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Feds resist control for 2nd most-abused pain drug
Yahoo/AP
Saturday, August 20, 2011 - 10:25pm
tags:
hydrocodone
Human Genome Evenly Poised
Yahoo/Zacks
Saturday, August 20, 2011 - 10:22pm
tags:
Human Genome Sciences
7 Large-Cap Global Pharma Dividend Stocks May Provide Appreciation and Income
Seeking Alpha
Saturday, August 20, 2011 - 10:21pm
tags:
Bristol-Myers Squibb, AstraZeneca, Eli Lilly, GSK, Merck, Sanofi, Pfizer
The Next Big Thing In Biotech: Nupathe (video)
The Street
Saturday, August 20, 2011 - 10:19pm
tags:
NuPathe, migraines, Zelrix
12 Biotech Stocks the Insiders Are Buying
Motley Fool
Saturday, August 20, 2011 - 10:09pm
tags:
Ligand, Halozyme, Ziopharm, OPKO Health, Theravance, Celgene, Human Genome Sciences, BioSante, Keryx, GTx, SIGA technologies, SciClone Pharmaceuticals
Biotech Gem Exelixis Is Compelling Only for the Long Term
Seeking Alpha
Saturday, August 20, 2011 - 10:03pm
tags:
Exelixis, cabozantinib, XL184
Merck-Ariad Drug Under EU Review
Yahoo/Zacks
Saturday, August 20, 2011 - 10:00pm
tags:
Merck, Ariad Pharmaceuticals, ridaforolimus, sarcoma
Does Approval Cause Automatic Gains any Longer?
Minyanville
Saturday, August 20, 2011 - 9:58pm
tags:
FDA
Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS™ (Brentuximab Vedotin) for Two Indications
Yahoo/BusinessWire
Saturday, August 20, 2011 - 9:56pm
tags:
systemic anaplastic large cell lymphoma, lymphoma, Hodgkin's lymphoma, Adcetris
DNA Sequencing: The Next High-Growth Market in Biotech?
Motley Fool
Saturday, August 20, 2011 - 9:54pm
tags:
DNA sequencing, Illumina, Life Technologies, Pacific Biosciences, Fluidigm, Complete Genomics
12 Cancer Stocks Being Snapped Up by Insiders
Seeking Alpha
Friday, August 19, 2011 - 12:09pm
tags:
OPKO Health, Tengion, GTx, Anadys, Complete Genomics, Amag Pharmaceuticals, MannKind, Threshold Pharmaceuticals, Synta, Genomic Health, Ziopharm, Ardea
Antares Pharma: A Promising Pharmaceutical Play
Seeking Alpha
Friday, August 19, 2011 - 11:17am
tags:
Antares, BioSante, LibiGel
How Undervalued Dendreon Is
Seeking Alpha
Friday, August 19, 2011 - 11:16am
tags:
Dendreon, Provenge, prostate cancer
Sandoz Sues Novo Nordisk to Head Off Generic Challenge on Diabetes Drug
Bloomberg
Friday, August 19, 2011 - 11:14am
tags:
Sandoz, Prandin, Novo Nordisk, Novartis, generics, diabetes
[video] The Next Big Thing in Biotech: Nupathe
TheStreet.com
Friday, August 19, 2011 - 11:13am
tags:
NuPathe, migraines, Zelrix
Could Vertex Sell $1 Billion Of Its Hepatitis C Drug This Year?
Forbes
Friday, August 19, 2011 - 10:58am
tags:
Vertex Pharmaceuticals, hepatitis C, Incivek
3 biotech stocks battle the ‘Dendreon Effect’ - Company’s troubles with Provenge chill fellow drug makers
Marketwatch
Friday, August 19, 2011 - 9:20am
tags:
Dendreon, Provenge, Savient, Human Genome Sciences, Vertex Pharmaceuticals, InterMune, Seattle Genetics
6 Companies That Could Revolutionize Medicine -- And Portfolios
Seeking Alpha
Friday, August 19, 2011 - 9:13am
tags:
Opexa, RXi Pharmaceuticals, Oncothyreon, Celldex, Advanced Cell Technologies, Keryx
Allos Therapeutics Starts Cancer Study
Yahoo/Zacks.com
Friday, August 19, 2011 - 9:10am
tags:
Allos, Folotyn, Amag Pharmaceuticals, T-cell lymphoma
7 Large-Cap Global Pharma Dividend Stocks May Provide Appreciation and Income
Seeking Alpha
Friday, August 19, 2011 - 9:08am
tags:
dividends, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GSK, Merck, Pfizer, Sanofi

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.